Category - Developments

Developments

Ripple and Glaukos ink evaluation and licensing agreements

Closely-held Ripple Therapeutics has announced evaluation and licensing agreements with Glaukos Corporation (NYSE:GKOS), enabling Glaukos to leverage Ripple’s proprietary technology platform to create sustained release...

October 15, 2024

Developments

Conavi completes go-public transaction

Conavi Medical has completed its reverse takeover of Titan Medical (TSX:TMD; OTC:TMDIF). The combined company (the Resulting Issuer), which will voluntarily delist from the TSX on or about October 15, 2024, and...

October 11, 2024

Developments

Aurinia presents new real-world data reinforcing LUPKYNIS in LN at ASN Kidney Week 2024

Aurinia Pharmaceuticals (NASDAQ:AUPH) has announced plans to present new data reinforcing the clinical significance of LUPKYNIS in the treatment of lupus nephritis (LN) at the American Society of Nephrology (ASN) Kidney...

October 11, 2024

Developments

Turnstone restructures to focus resources on advancing Phase 1 study

Turnstone Biologics (NASDAQ:TSBX) has announced restructuring initiatives that include the strategic prioritization of its pipeline, a 60% workforce reduction, and changes to its leadership team, aimed at focusing...

October 11, 2024

Developments

Health Canada clears Palisade to commence Phase 1 study of PALI-2108 in UC

Palisade Bio (NASDAQ:PALI) has announced that it has received a No Objection Letter from Health Canada for its Phase 1 clinical trial of PALI-2108 for the treatment of ulcerative colitis (UC). The orally-administered...

October 10, 2024

Developments

Clearmind receives IRB approval for trial of CMND-100 for AUD at second clinical site

Clearmind Medicine (NASDAQ:CMND) has announced that it has received Institutional Review Board (IRB) approval from one of its U.S. clinical sites for part A of its Phase I/IIa clinical trial of CMND-100 for the...

October 10, 2024

Developments

SI-BONE reports first in-patient procedures with TNT implant system for pelvic fractures

SI-BONE (NASDAQ:SIBN) has announced the first in-patient procedures using its iFuse TORQ TNT Implant System (TNT), designed to address anatomic and biomedical challenges of pelvic fragility fractures as opposed to...

October 10, 2024

Developments

Perimeter completes patient enrollment for pivotal trial evaluating next-gen OCT B-Series with ImgAssist AI in breast cancer surgery

Perimeter Medical Imaging AI (TSXV:PINK; OTC:PYNKF) has announced the completion of patient enrollment in a pivotal clinical study evaluating its next-generation Perimeter B-Series OCT system, which combines proprietary...

October 3, 2024

Developments

Valerio acquires oncology biotech, Emglev

Valerio Therapeutics (Euronext Paris:ALVIO) has announced the acquisition of closely-held Emglev Therapeutics, a single-domain antibody-based therapeutic company and spinoff of Institut Curie, a leading cancer center in...

September 30, 2024

Developments

IRLAB enrolls last patient in trial of Pirepemat for Parkinson’s

IRLAB Therapeutics (STO:IRLAB-A; FRA:6IRA) has announced that it has enrolled the last patient in its ongoing Phase IIb study of Pirepemat for Parkingson’s disease. The company also reports that a reduction in falls has...

September 30, 2024

Category - Developments

Ripple and Glaukos ink evaluation and licensing agreements

Conavi completes go-public transaction

Aurinia presents new real-world data reinforcing LUPKYNIS in LN at ASN Kidney Week 2024

Turnstone restructures to focus resources on advancing Phase 1 study

Health Canada clears Palisade to commence Phase 1 study of PALI-2108 in UC

Clearmind receives IRB approval for trial of CMND-100 for AUD at second clinical site

SI-BONE reports first in-patient procedures with TNT implant system for pelvic fractures

Perimeter completes patient enrollment for pivotal trial evaluating next-gen OCT B-Series with ImgAssist AI in breast cancer surgery

Valerio acquires oncology biotech, Emglev

IRLAB enrolls last patient in trial of Pirepemat for Parkinson’s

General

More